Aspen Pharmacare’s investment case is largely underpinned by the Group’s manufacturing facility

Aspen Pharmacare’s investment case is largely underpinned by the Group’s manufacturing facility

Aspen Pharmacare’s sterile manufacturing facility is expected to add R2bn from a contribution perspective in 2024 and R4bn in 2025 as the Group benefits from its significant manufacturing capacity. Aspen Pharmacare Group CEO Stephen Saad is in the C-SUITE and as upbeat as ever despite the tough operating environment that hit the group hard in it’s first half results reported earlier today .

Watch all our videos for In The C-Suite.